Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma?
- Resource Type
- Academic Journal
- Authors
- Hung MH; Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI, Bethesda, Maryland.; Wang XW; Laboratory of Human Carcinogenesis, Center for Cancer Research, NCI, Bethesda, Maryland.; Liver Cancer Program, Center for Cancer Research, NCI, Bethesda, Maryland.
- Source
- Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE
- Subject
- Language
- English
In a recent study, Rialdi and colleagues identified a specific vulnerability in β-catenin mutant hepatocellular carcinoma (HCC) via EZH2-mediated suppression of WNT signaling and revealed the selective anti-HCC activity of WNTinib, a chemical derivative of regorafenib and sorafenib in targeting this vulnerability. Their discoveries highlight the role of EZH2 in modulating WNT signaling and suggest an implication of WNTinihb as a small-molecule inhibitor for the treatment of HCC with activated WNT/β-catenin.
(©2023 American Association for Cancer Research.)